Gene therapy for cancer: What have we done and where are we going?

Journal of the National Cancer Institute

Volumn 89, Issue 1, 1997, Pages 21-39

  Roth, Jack A ^a,b   Cristiano, Richard J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LYMPHOKINE; PRODRUG; RECOMBINANT DNA; VIRUS VECTOR;

CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG SENSITIZATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; ONCOGENE; REVIEW; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE;

EID: 0031025998     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.1.21     Document Type: Review

References (152)

1. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995;270:475-80.
2. Kiem HP, von Kalle D, Schuening F, Storb R. Gene therapy and bone marrow transplantation [see comment citation in Medline]. Curr Opin Oncol 1995;7:107-14.
3. Miller N, Vile R. Targeted vectors for gene therapy. FASEB J 1995;9: 190-9.
4. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995;270:404-10.
5. Herrmann F. Cancer gene therapy: principles, problems, and perspectives. J Mol Med 1995;73:157-63.
6. Descamps V, Duffour MT, Mathieu MC, Fernandez N, Cordier L, Abina MA, et al. Strategies for cancer gene therapy using adeno virus vectors; adeno virus vector-mediated gene transfer for prodrug activation, adoptive immunotherapy and cytokine-mediated gene therapy. J Mol Med 1996; 74:183-9.
7. Blaese M, Blankenstein T, Brenner M, Cohen-Haguenauer O, Gansbacher G, Russell S, et al. Vectors in cancer therapy: how will they deliver? Cancer Gene Ther 1995;4:291-7.
8. Torres JM. The importance of accurate terminology in the field of human gene transfer [editorial]. Hum Gene Ther 1995;6:133-5.
9. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
10. Asher AL, Mule JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 1991;146:3227-34.
11. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
12. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50:7820-5.
13. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
14. Karp SE, Farber A, Salo JC, Hwu P, Jaffe G, Asher AL, et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. J Immunol 1993; 150:896-908.
15. Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M, et al. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 1993;53:471-7.
16. Tsai SC, Gansbacher B, Tait L, Miller FR, Heppner GH. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 1993;85:546-53.
17. + T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992;175:1423-31.
18. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH, et al. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 1992;52:6229-36.
19. Gansbacher B, Zier K, Cronin K, Hantzopoulos PA, Bouchard B, Houghton A, et al. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood 1992;80:2817-25.
20. Nerrouche Y, Negrier S, Bain C, Combaret V, Mercatello A, Coronel B, et al. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 1995;13:410-8.
21. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87:280-5.
22. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-8.
23. Rosenberg SA. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Sci Am 1995;1: 90-100.
24. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340-7.
25. Grimm EA, Crump WL 3d, Durett A, Hester JP, Lagoo-Deenadalayan S, Owen-Schaub LB. TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol Immunother 1988;27: 53-8.
26. Subcommittee on Data Management. RAC Data Management Report. Members, R.D. editor. Bethesda (MD): National Institutes of Health 1995;2-51.
27. The RAC & Worldwide Gene Therapy Report. Paris. TMC Development, 1995.
28. Herrmann E. Clinical application of gene transfer. J Mol Med 1996;74: 213-21.
29. Sobol RE, Scanlan KJ. The internet book of gene therapy cancer therapeutics. Stamford (CT): Appleton & Lange, 1995.
30. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors [see comment citations in Medline]. Science 1992;256:1550-2.
31. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53: 5274-83.
32. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993;4:725-31.
33. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994;54:6228-34.
34. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995;6:1055-63.
35. Khil MS, Kim JH, Mullen CA, Kim SH, Freytag SO. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine-deaminase gene: retrovirus vector-mediated gene transfer, prodrug activation and irradiation for improved tumor therapy. Clin Cancer Res 1996;2:53-7.
36. Clinical protocols. Cancer Gene Ther 1995;2:67-74.
37. ORDA Reports, Recombinant DNA Advisory Committee (RAC) data management report - December 1994. Hum Gene Ther 1995;6:535-48.
38. Mickisch GH, Aksentijevich I, Schoenlein PV, Goldstein LJ, Galski H, Stahle C, et al. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 1992;79: 1087-93.
39. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of the human MDR1. Science 1992;257:99-103.
40. Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res 1995;55:2608-14.
41. May C, Gunther R, McIvor RS. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate-reductase activity. Blood 1995;86:2439-48.
42. Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP. A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 1996;87:2579-87.
43. Weinberg RA. Tumor suppressor genes. Science 1991;254:1138-46.
44. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64:235-48.
45. Marshall CJ. How does p21ras transform cells? Trends Genet 1991;7: 91-5.
46. Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991;51:1744-8.
47. Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res 1991;51:4505-10.
48. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993;4:451-60.
49. Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 1993;53:1743-6.
50. Grim J, Deshane J, Loechel F, Conry R, Siegel G, Feng M, et al. Induction of apoptotic cell death in erbB-2 over-expressing tumor cells of diverse histologic subtypes mediated by intracellular localization of an anti-erbB-2 SFV [abstract]. Cancer Gene Ther 1994;1:333-4.
51. Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 1994;54:900-2.
52. Scanlon K, Jiao L, Funato T, Wang W, Tone T. Ribozyme-mediated cleavages of c-fos mRNA reduce gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci U S A 1991;88:10591-5.
53. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995;55:2024-8.
54. Chang EH, Miller PS, Cushman C, Devadas K, Pirollo KF, Ts'o PO, et al. Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry 1991;30:8283-6.
55. Richardson JH, Marasco WA. Intracellular antibodies: development and therapeutic potential. Trends Biotechnol 1995;13:306-10.
56. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
57. Knudson AG, Upton AC. Tumor suppressor gene workshop. Cancer Res 1990;50:6765.
58. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995;11:199-210.
59. Takahashi T, Carbone D, Nau MM, Hida T, Linnoila I, Ueda R, et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992;52:2340-3.
60. Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva C, et al. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 1992;12:1387-95.
61. Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T, Roth JA. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 1993;4:617-24.
62. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model [see comment citation in Medline]. J Natl Cancer Inst 1994;86:1458-62.
63. Wang J, Bucana CD, Roth JA, Zhang WW. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1995;2:9-17.
64. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994;54:3662-7.
65. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Geopfert H, Taylor DL, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55:1-6.
66. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Proc Am Assoc Cancer Res 1995;36:423.
67. Yung WK, Shi YX, Zhang WW, Roth JA, Steck PA. Growth suppression of human glioma cells by restoration of wild-type p53 gene utilizing an adenovirus vector [abstract]. Proc Am Assoc Cancer Res 1995;36:423.
68. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, Shaked A. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 1996;155:753-6.
69. Badie B, Drazan KE, Kramar MH, Shaked A, Black KL. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol Res 1995;17:209-16.
70. Drazen KE, Shen XD, Csete ME, Zhang WW, Roth JA, Busuttil RW, et al. In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection. Surgery 1994;116:197-203.
71. Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Johnson DE, et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 1996;3:121-30.
72. Jin X, Nguyen D, Zhang WW, Kyritsis AP, Roth JA. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res 1995;55:3250-3.
73. Xu HJ, Zhou Y, Seigne J, Perng GS, Mixon M, Zhang C, et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 1996;56:2245-9.
74. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038-42.
75. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
76. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenoviral-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-91.
77. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993;4:451-60.
78. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993;53:4129-33.
79. Hodgson CP. The vector void in gene therapy: can viral vectors and transfection be combined to permit safe, efficacious, and targeted gene therapy? BioTechnology 1995;13:222-5.
80. Habib NA, Ding S, El-Masry R, Dalla Serra G, Mikhail NE, Izzi G, et al. Contrasting effects of direct p53 DNA injection in primary and secondary liver tumours. Tumor Targeting 1995;1:295-8.
81. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988;167:400-6.
82. Heinrich MC, Keeble WW, Grompe M Bagby GC Jr, Hoatlin ME. A gibbon ape leukemia virus (GALV) pseudotyped retro viral vector for gene therapy of Fanconi anemia complementation group C (FACC). Blood 1994;84:359a.
83. Yam P, Chow W, Zaia JA, Yee JK. Comparison of pseudo-type and amphotropic retro viral mediated gene transfer into human hematopoietic progenitors and cell lines. Cancer Gene Ther 1995;2:323.
84. Spiegel M, Gregor M, Lauer U. Generation of recombinant hepatotropic retro-viral pseudotypes for usage in liver-restricted in vivo gene therapy. Gut 1995;37:A133-4.
85. Li QT, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993;4:403-9.
86. Mittal SK, Bett AJ, Prevec L, Graham FL. Foreign gene expression by human adenovirus type 5-based vectors studied using firefly luciferase and bacterial beta galactosidase genes as reporters. Virology 1995;210: 226-30.
87. Kremer EJ, Perricaudet M. Adenovirus and adeno-associated virus mediated gene transfer. Br Med Bull 1995;51:31-44.
88. Engelhardt JF, Simon RH, Yang Y, Zepeda M, Weber-Pendleton S, Doranz B, et al. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum Gene Ther 1993; 4:759-69.
89. Sobol R, Scanlon KJ. Clinical protocols list. Cancer Gene Ther 1995;2: 225-34.
90. Engelhardt JF, Ye X, Doranz B, Wilson JM, Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A 1994;91:6196-200.
91. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994;91:4407-11.
92. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994;5:1217-29.
93. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996;217:11-22.
94. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung [see comment citation in Medline]. Nat Med 1995;1:890-3.
95. Dai Y, Schwarz EM, Gu D, Zhang W, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of both factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995;92:1401-5.
96. Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995;6:1039-44.
97. Roth JA. Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wild-type (normal) p53. Hum Gene Ther 1996;7:861-74.
98. Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A 1993;90:10613-7.
99. Halbert CL, Alexander IE, Wolgamot GM, Miller AD. Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells. J Virol 1995;69:1473-9.
100. Latchman DS. Herpes simplex virus vectors for gene therapy. Mol Biotechnol 1994;2:179-95.
101. Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta. Ann Surg Oncol 1995;2:151-9.
102. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 co-stimulatory molecules. Cancer Res 1994;54:5552-5.
103. Wilkinson GW, Borysiewicz LK. Gene therapy and viral vaccination: the interface. Br Med Bull 1995;51:205-16.
104. Forstova J, Krauzewicz N, Sandig V, Elliott J, Palkova Z, Strauss M, et al. Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells. Hum Gene Ther 1995;6:297-306.
105. Nabel EG, Gordon D, Yang ZY, Xu L, San H, Plautz G, et al. Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther 1992;3:649-56.
106. Das PK, Murray GJ, Zirzow GC, Brady RO, Barranger JA. Lectin-specific targeting of beta-glucocerebrosidase to different liver cells via glycosylated liposomes. Biochem Med 1985;33:124-31.
107. Wu GY, Wu CH. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. [published erratum appears in J Biol Chem 1988;263:588]. J Biol Chem 1987;262:4429-32.
108. Wagner E, Zenke M, Cotten M, Beug H, Birnstiel ML. Transferrinpolycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci U S A 1990;87:3410-4.
109. Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SL. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci U S A 1993;90:11548-52.
110. Bunnell BA, Askari FK, Wilson JM. Targeted delivery of antisense oligonucleotides by molecular conjugates. Somat Cell Mol Genet 1992;18:559-69.
111. Cotten M, Wagner E, Zatloukal K, Philips S, Curiel DT, Birnstiel ML. High-efficiency receptor-mediated delivery of small and large (48 kilo-base) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci U S A 1992;89:6094-8.
112. Gao L, Wagner E, Cotten M, Agarwal S, Harris C, Romer M, et al. Direct in vivo gene transfer to airway epithelium employing adenovirus-polylysine-DNA complexes. Hum Gene Ther 1993;4:17-24.
113. Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum Gene Ther 1993;4:151-9.
114. Acsadi G, Jiao SS, Jani A, Duke D, Williams P, Chong W, et al. Direct gene transfer and expression into rat heart in vivo. New Biol 1991;3:71-81.
115. Cheng L, Ziegelhoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci U S A 1993;90:4455-9.
116. Nicolet CM, Burkholder JK, Gan J, Culp J, Kashmiri SV, Schlom J, et al. Expression of a tumor-reactive antibody-interleukin 2 fusion protein after in vivo particle-mediated gene delivery. Cancer Gene Ther 1995;2:161-70.
117. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors only in cells that are actively replicating at the time of infection [published erratum appears in Mol Cell Biol 1992;12:433]. Mol Cell Biol 1990;10: 4239-42.
118. Cristiano RJ, Smith LC, Woo SL. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci U S A 1993;90:11548-52.
119. Curiel DT, Wagner E, Cotten M, Birnstiel ML, Agarwal S, Li C, et al. High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum Gene Ther 1992;3:147-54.
120. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions [see comment citation in Medline]. Science 1994;266:1373-6.
121. Gottschalk S, Cristiano RJ, Smith L, Woo SL. Folate receptor-mediated DNA delivery and expression in vitro. Gene Ther 1994;1:185-91.
122. Ding Z, Cristiano R, Roth JA, Takacs B, Kuo MT. Malaria circumsporozoite protein is a novel gene delivery vehicle to primary hepatocyte cultures and cultured cells. J Biol Chem 1995;270:3667-76.
123. Cristiano R, Roth J. Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther 1996;3:4-10.
124. Muller M, Gissmann L, Cristiano RJ, Sun XY, Frazer IH, Jenson AB, et al. Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol 1995;69:948-54.
125. Ghazal P, Lubon H, Fleckenstein B, Hennighausen L. Binding of transcription factors and creation of a large nucleoprotein complex on the human cytomegalovirus enhancer. Proc Natl Acad Sci U S A 1987;84: 3658-62.
126. Ponder KP, Dunbar RP, Wilson DR, Darlington GJ, Woo SL. Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection. Hum Gene Ther 1991;2:41-52.
127. DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994;116:205-13.
128. Smith MJ, Rousculp MD, Goldsmith KT, Curiel DT, Garver RK Jr. Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. Hum Gene Ther 1994;5:29-35.
129. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993;53:962-7.
130. Gazit G, Kane SE, Nichols P, Lee AS. Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo. Cancer Res 1995;55:1660-3.
131. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994; 5:1079-88.
132. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma [see comment citation in Medline]. Ann Thorac Surg 1994;57:1395-401.
133. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, et al. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol 1995;154:3406-19.
134. Bernad A, Varas F, Gallego JM, Almendral JM, Bueren JA. Ex vivo expansion and selection of retrovirally transduced bone marrow: an efficient methodology for gene-transfer to murine lympho-haemopoietic stem cells. Br J Haematol 1994;87:6-17.
135. Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, Rosenberg SA, et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 1995;55:748-52.
136. Weijtens M, Willemsen R, Valerio D, Stam K, Bolhuis R. Functional expression of a single chain Fv/g receptor with renal cell carcinoma specificity in activated human PBL; single chain antibody Fv fragment and FceRI receptor fusion gene expression in cytotoxic T-lymphocyte or peripheral blood lymphocyte using LXSN retro virus vector [abstract]. J Mol Med 1995;73:B13-B13.
137. Rosenfeld MA, Chu CS, Seth P, Danel C, Banks T, Yoneyama K, et al. Gene transfer to freshly isolated human respiratory epithelial cells in vitro using a replication-deficient adenovirus containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther 1994;5:331-42.
138. Weichselbaum RR, Hallahan DE, Beckett MA, Mauceri HJ, Lee H, Sukhatme VP, et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994;54:4266-9.
139. Son K, Huang L. Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer. Proc Natl Acad Sci U S A 1994;91:12669-72.
140. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci U S A 1995;92:2577-81.
141. Crystal RG, McElvaney NG, Rosenfeld MA, Chu C, Mastrangeli A, Hay JG, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis [see comment citation in Medline]. Nat Genet 1994;8:42-51.
142. Ginsberg HS, Horswood RL, Chanock RM, Prince GA. Role of early genes in pathogenesis of adenovirus pneumonia [published erratum appears in Proc Natl Acad Sci U S A 1991;88:681]. Proc Natl Acad Sci U S A 1990;87:6191-5.
143. Ginsberg HS, Moldawer LL, Sehgal PB, Redington M, Kilian PL, Chanock RM, et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A 1991;88: 1651-5.
144. Ginsberg HS, Lundholm-Beauchamp U, Horswood RL, Pernis B, Wold WS, Chanock RM, et al. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci U S A 1989;86:3823-37.
145. Zhang W, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA. Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther 1995; 6:155-64.
146. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-9.
147. Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, et al. p53 protein accumulated frequently in early bronchial neoplasia. Cancer Res 1993;53:4817-22.
148. Stribling R, Brunette E, Liggitt D, Gaensler K, Debs R. Aerosol gene delivery in vivo. Proc Natl Acad Sci U S A 1992;89:11277-81.
149. Nabel EG, Yang Z, Muller D, Chang AE, Gao X, Huang L, et al. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum Gene Ther 1994;5:1089-94.
150. Sobol RE, Fakhrai H, Shawler D, Gjerset R, Dorigo O, Carson C, et al. Interleukin-2 gene therapy in a patient with glioblastoma; using a retrovirus vector. Gene Ther 1995;2:164-7.
151. Habib NA, Ding SF, El-Masry R, Mitry RR, Honda K, Michail NE, et al. Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev 1996;20:103-7.
152. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retroviral-mediated wildtype p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-91.